<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13726">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02928224</url>
  </required_header>
  <id_info>
    <org_study_id>ARRAY-818-302</org_study_id>
    <secondary_id>2015-005805-35</secondary_id>
    <nct_id>NCT02928224</nct_id>
  </id_info>
  <brief_title>Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer</brief_title>
  <acronym>BEACON CRC</acronym>
  <official_title>A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5- Fluorouracil (5-FU)/Folinic Acid (FA) /Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Array BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pierre Fabre Medicament</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Array BioPharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, open-label, 3-arm Phase 3 study to evaluate encorafenib +
      cetuximab plus or minus binimetinib versus Investigator's choice of either
      irinotecan/cetuximab or FOLFIRI/cetuximab, as controls, in patients with BRAFV600E mCRC
      whose disease has progressed after 1 or 2 prior regimens in the metastatic setting. The
      study contains a Safety Lead-in Phase in which the safety and tolerability of encorafenib +
      binimetinib + cetuximab will be assessed prior to the Phase 3 portion of the study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(Safety Lead-in) Incidence of dose-limiting toxicities (DLTs)</measure>
    <time_frame>Cycle 1 (up to 28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(Safety Lead-in) Incidence and severity of adverse events (AEs) and changes in clinical laboratory parameters, vital signs, electrocardiograms (ECGs), echocardiogram (ECHO)/multi-gated acquisition (MUGA) scans and ophthalmic examinations</measure>
    <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(Safety Lead-in) Incidence of dose interruptions, dose modifications and discontinuations due to adverse events (AEs)</measure>
    <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(Phase 3) Overall Survival (OS) of Triplet Arm vs. Control Arm</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Response Rate (ORR)</measure>
    <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Duration of Response (DOR)</measure>
    <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Time to Response</measure>
    <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Overall Survival (OS) in Doublet Arm vs. Control Arm and Triplet Arm vs. Doublet Arm</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Progression-free Survival (PFS) in study arms</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Objective Response Rate (ORR) in study arms</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Duration of Response (DOR) in study arms</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Time to Response in study arms</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Incidence and severity of adverse events (AEs) and changes in clinical laboratory parameters, vital signs, electrocardiograms (ECGs), echocardiogram (ECHO)/multi-gated acquisition (MUGA) scans and ophthalmic examinations</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of the Quality of Life in study arms</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the area under the concentration-time curve (AUC) for cetuximab, encorafenib, binimetinib, and a metabolite of binimetinib</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the maximum concentration (Cmax) for cetuximab, encorafenib, binimetinib, and a metabolite of binimetinib</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the time of maximum observed concentration (Tmax) for cetuximab, encorafenib, binimetinib, and a metabolite of binimetinib</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the steady-state concentration measured just before the next dose of study drug (Ctrough) for cetuximab, encorafenib, binimetinib, and a metabolite of binimetinib</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">645</enrollment>
  <condition>BRAF V600E-mutant Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Safety Lead-in, Triplet Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Encorafenib + binimetinib + cetuximab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doublet Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Encorafenib + cetuximab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Encorafenib</intervention_name>
    <description>Orally, once daily.</description>
    <arm_group_label>Safety Lead-in, Triplet Arm</arm_group_label>
    <arm_group_label>Doublet Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Binimetinib</intervention_name>
    <description>Orally, twice daily.</description>
    <arm_group_label>Safety Lead-in, Triplet Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Standard of care.</description>
    <arm_group_label>Safety Lead-in, Triplet Arm</arm_group_label>
    <arm_group_label>Doublet Arm</arm_group_label>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Standard of care.</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic Acid</intervention_name>
    <description>Standard of care.</description>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>FA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil</intervention_name>
    <description>Standard of care.</description>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>5-FU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Age ≥ 18 years at time of informed consent

          -  Histologically- or cytologically-confirmed CRC that is metastatic

          -  Presence of BRAFV600E in tumor tissue as previously determined by a local assay at
             any time prior to Screening or by the central laboratory

          -  Progression of disease after 1 or 2 prior regimens in the metastatic setting

          -  Evidence of measurable or evaluable non-measurable disease per RECIST, v1.1

          -  Adequate bone marrow, cardiac, kidney and liver function

          -  Able to take oral medications

          -  Female patients are either postmenopausal for at least 1 year, are surgically sterile
             for at least 6 weeks, or must agree to take appropriate precautions to avoid
             pregnancy from screening through follow-up if of childbearing potential

          -  Males must agree to take appropriate precautions to avoid fathering a child from
             screening through follow-up

        Key Exclusion Criteria:

          -  Prior treatment with any RAF inhibitor, MEK inhibitor, cetuximab, panitumumab or
             other EGFR inhibitors

          -  Prior irinotecan hypersensitivity or toxicity that would suggest an inability to
             tolerate irinotecan 180 mg/m2 every 2 weeks

          -  Symptomatic brain metastasis or leptomeningeal disease

          -  History or current evidence of retinal vein occlusion or current risk factors for
             retinal vein occlusion (e.g., uncontrolled glaucoma or ocular hypertension, history
             of hyperviscosity or hypercoagulability syndromes)

          -  Known history of acute or chronic pancreatitis

          -  History of chronic inflammatory bowel disease or Crohn's disease requiring medical
             intervention (immunomodulatory or immunosuppressive medications or surgery) ≤12
             months prior to randomization

          -  Uncontrolled blood pressure despite medical treatment

          -  Impaired GI function or disease that may significantly alter the absorption of
             encorafenib or binimetinib (e.g., ulcerative diseases, uncontrolled vomiting,
             malabsorption syndrome, small bowel resection with decreased intestinal absorption)

          -  Concurrent or previous other malignancy within 5 years of study entry, except cured
             basal or squamous cell skin cancer, superficial bladder cancer, prostate
             intraepithelial neoplasm, carcinoma in-situ of the cervix, or other noninvasive or
             indolent malignancy

          -  History of thromboembolic or cerebrovascular events ≤ 6 months prior to starting
             study treatment, including transient ischemic attacks, cerebrovascular accidents,
             deep vein thrombosis or pulmonary emboli

          -  Concurrent neuromuscular disorder that is associated with the potential of elevated
             CK (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis,
             spinal muscular atrophy)

          -  Residual CTCAE ≥ Grade 2 toxicity from any prior anticancer therapy, with the
             exception of Grade 2 alopecia or Grade 2 neuropathy

          -  Known history of HIV infection

          -  Active hepatitis B or hepatitis C infection

          -  Known history of Gilbert's syndrome

          -  Known contraindication to receive cetuximab or irinotecan at the planned doses
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Array BioPharma, Inc.</last_name>
    <role>Study Director</role>
    <affiliation>303-381-6604</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Array BioPharma, Inc.</last_name>
    <phone>303-381-6604</phone>
    <email>clinicaltrials@arraybiopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Compassionate Cancer Care Medical Group, Inc. - Corona</name>
      <address>
        <city>Corona</city>
        <state>California</state>
        <zip>92879</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>951-371-2411</phone>
    </contact>
    <investigator>
      <last_name>Haresh Jhangiani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope - Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>626-256-4673</phone>
      <phone_ext>63087</phone_ext>
    </contact>
    <investigator>
      <last_name>Marwan Fakih, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Compassionate Care Research Group, Inc.</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Lepthien</last_name>
      <phone>714-698-0300</phone>
    </contact>
    <investigator>
      <last_name>Peyman Salimi-Tari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Compassionate Cancer Care Medical Group</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corina King</last_name>
      <phone>951-276-2760</phone>
    </contact>
    <investigator>
      <last_name>Brian Choi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital - Anschutz Cancer Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Szilard</last_name>
      <phone>720-848-0702</phone>
    </contact>
    <investigator>
      <last_name>Christopher Lieu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamil Sadowski</last_name>
      <phone>203-785-6661</phone>
    </contact>
    <investigator>
      <last_name>Howard Hochster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Hersch</last_name>
      <phone>646-888-1377</phone>
    </contact>
    <investigator>
      <last_name>Rona Yaeger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ibrahim Abukenda</last_name>
      <phone>206-341-8993</phone>
    </contact>
    <investigator>
      <last_name>Bruce Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates, P.S.</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>509-462-2275</phone>
    </contact>
    <investigator>
      <last_name>Chaudhry Arvind, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Bonheiden</city>
        <state>Antwerpen</state>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Array Biopharma Investigative Site</name>
      <address>
        <city>Edegem</city>
        <state>Antwerp</state>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Noord-Holland</city>
        <state>Amsterdam</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Heidelberglaan</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Array Biopharma Investigative Sites (2)</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 21, 2017</lastchanged_date>
  <firstreceived_date>August 16, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal cancer</keyword>
  <keyword>BRAF</keyword>
  <keyword>BRAFV600E</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
